Reading time: 4 minutes Chris Wang Unlike the Merriam Webster definition of promiscuous, describing a kinase inhibitor as promiscuous actually refers to the number of kinases it inhibits. The more promiscuous an inhibitor is, the higher number of off-targets it has. Traditional drug development strategies avoid promiscuous compounds because off-target effects can lead to side... Continue Reading →
Reading time: 5 minutes Chris Wang Like Keanu Reeves dodging bullets within The Matrix, cancer cells can dodge even carefully designed anti-cancer agents. Scientists strive to design “silver bullets,” ones which target cancer cells while sparing healthy normal cells. This "silver bullet" approach is appealing to researchers due to the promise of improved therapeutic response... Continue Reading →
Reading time: 4 minutes Brittany Avin McKelvey We are in a hayday for cancer therapies, as research has surpassed traditional chemotherapeutics. New drugs, new treatment regimens, and even new drug classes are approved each day, broadening the horizons of oncology. The newest types of drugs to recently gain FDA approval are tissue agnostic drugs. (See... Continue Reading →
OncoBites 